Ablynx NV is taking back rights to two programmes for antibody-derived therapeutic proteins from Pfizer Inc following the US company’s decision to drop the products from its portfolio. Ablynx’s shares dropped by about 18% on the day. ---Subscribe to MedNous to access this article--- Company News
